Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

Luis Jara-Palomares; Behnood Bikdeli; David Jiménez; Alfonso Muriel; Pablo Demelo-Rodríguez; Isabelle Mahé; Juan José López-Núñez; Joaquín Alfonso Megido; Begoña Fernández Jiménez; Manuel Monreal; RIETE Investigators

doi:10.1111/eci.14310

Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

Eur J Clin Invest. 2024 Dec;54(12):e14310. doi: 10.1111/eci.14310. Epub 2024 Sep 4.

Authors

Luis Jara-Palomares^{1

2}, Behnood Bikdeli^{3

4

5

6}, David Jiménez^{2

7}, Alfonso Muriel^{8

9}, Pablo Demelo-Rodríguez¹⁰, Isabelle Mahé^{11

12

13}, Juan José López-Núñez^{2

14

15

16}, Joaquín Alfonso Megido¹⁷, Begoña Fernández Jiménez¹⁸, Manuel Monreal^{2

19}; RIETE Investigators

Collaborators

RIETE Investigators:
Paolo Prandoni, Benjamin Brenner, Dominique Farge-Bancel, Raquel Barba, Pierpaolo Di Micco, Laurent Bertoletti, Sebastian Schellong, Inna Tzoran, Abilio Reis, Marijan Bosevski, Henri Bounameaux, Radovan Malý, Peter Verhamme, Joseph A Caprini, Hanh My Bui, M D Adarraga, A Alberich-Conesa, J Aibar, A Alda-Lozano, J Alfonso, J Alonso-Carrillo, C Amado, M Angelina-García, J I Arcelus, A Ballaz, R Barba, M Barca-Hernando, C Barbagelata, M Barrón, B Barrón-Andrés, F Beddar-Chaib, A Blanco-Molina, J C Caballero, G Castellanos, L Chasco, J Criado, C De Ancos, J Del Toro, C De Juana-Izquierdo, A M Díaz-Brasero, J A Díaz-Peromingo, A Dubois-Silva, J C Escribano, C Falgá, A I Farfán-Sedano, C Fernández-Aracil, C Fernández-Capitán, B Fernández-Jiménez, J L Fernández-Reyes, M A Fidalgo, I Francisco, C Gabara, F Galeano-Valle, F García-Bragado, A García-Ortega, O Gavín-Sebastián, M A Gil De Gómez, A Gil-Díaz, C Gómez-Cuervo, A González-Munera, E Grau, L Guirado, J Gutiérrez, L Hernández-Blasco, M J Jaras, R Jiménez, I Jou, M D Joya, S Lainez-Justo, A Lalueza, R Lecumberri, J M León-Ramírez, P Llamas, J L Lobo, P López-Miguel, A López-Ruiz, J B López-Sáez, A Lorenzo, M Lumbierres, O Madridano, A Maestre, P J Marchena, M Marcos, M Martín Del Pozo, F Martín-Martos, J M Maza, E Mena, M I Mercado, J Moisés, M V Morales, M S Navas, J A Nieto, M J Núñez-Fernández, M Olid, L Ordieres-Ortega, M Ortiz, J Osorio, S Otálora, R Otero, N Pacheco-Gómez, J Pagán, A C Palomeque, E Paredes, P Parra-Caballero, J M Pedrajas, C Pérez-Ductor, M Pérez-Pinar, M L Peris, M L Pesce, J A Porras, R Puchades, F Rivera-Cívico, A Rodríguez-Cobo, V Rosa, M Romero-Brugera, P Ruiz-Artacho, N Ruiz-Giménez, J Ruiz-Ruiz, G Salgueiro, T Sancho, V Sendín, P Sigüenza, S Soler, S Suárez-Fernández, R Tirado, A Torrents-Vilar, M I Torres, J Trujillo-Santos, F Uresandi, R Valle, J F Varona, A Villalobos, P Villares, C Ay, S Nopp, I Pabinger, M Engelen, T Vanassche, P Verhamme, Hhb Yoo, A C Montenegro, S N Morales, J Roa, J Hirmerova, R Malý, L Bertoletti, A Bura-Riviere, J Catella, R Chopard, F Couturaud, O Espitia, C Grange, B Leclercq, R Le Mao, F Moustafa, L Plaisance, G Sarlon-Bartoli, P Suchon, E Versini, S Schellong, B Brenner, N Dally, I Tzoran, P Sadeghipour, F Rashidi, A Abenante, G Barillari, M Basaglia, F Bilora, D Bissacco, C Bortoluzzi, B Brandolin, R Casana, M Ciammaichella, D Colaizzo, F Dentali, P Di Micco, E Grandone, E Imbalzano, D Lambertenghi-Deliliers, F Negro, R Pesavento, A Poz, P Prandoni, P Scarinzi, C Siniscalchi, B Taflaj, A Tufano, A Visonà, N Vo Hong, B Zalunardo, A Skride, D Kigitovica, S Fonseca, R Marques, J Meireles, S Pinto, M Bosevski, A Eftimova, M Zdraveska, H Bounameaux, L Mazzolai, A Aujayeb, J A Caprini, I Weinberg, H M Bui

Affiliations

¹ Respiratory Department, Virgen del Rocio Hospital and Instituto de Biomedicina, Sevilla, Spain.
² CIBERES, Carlos III Health Institute, Madrid, Spain.
³ Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
⁴ Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
⁵ YNHH/Yale Center for Outcomes Research and Evaluation (CORE), New Haven, Connecticut, USA.
⁶ Cardiovascular Research Foundation (CRF), New York, New York, USA.
⁷ Respiratory Department, Hospital Ramón y Cajal and Universidad de Alcalá (IRYCIS), Madrid, Spain.
⁸ Biostatistics Department, Ramón y Cajal Hospital and Instituto Ramón y Cajal de Investigacion Sanitaria IRYCIS, CIBERESP, Madrid, Spain.
⁹ University of Alcala, Madrid, Spain.
¹⁰ Department of Internal Medicine, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
¹¹ Department of Internal Medicine, Hôpital Louis Mourier, Assistance Publique des Hôpitaux de Paris (AP-HP), Colombes, France.
¹² Université Paris Cité, Paris, France.
¹³ INSERM UMR-S-1140, Paris, France.
¹⁴ Department of Internal Medicine, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
¹⁵ Department of Medicine, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain.
¹⁶ Institut de Recerca Germans Trias i Pujol, Badalona, Barcelona, Spain.
¹⁷ Department of Internal Medicine, Hospital Valle del Nalón, Langreo, Asturias, Spain.
¹⁸ Department of Hematology, Hospital Universitario de Móstoles, Móstoles, Madrid, Spain.
¹⁹ Faculty of Health Sciences, UCAM - Universidad Católica San Antonio de Murcia, Murcia, Spain.

PMID: 39233322
DOI: 10.1111/eci.14310

Abstract

This study generated evidence to guide anticoagulation in patients with VTE after vaccination for COVID-19. We provided data on the low recurrence rate after cessation of anticoagulant therapy and the findings for this study offer timely insights into the management of a potentially vaccine-related adverse event.

Keywords: COVID‐19; COVID‐19 vaccines; anticoagulation therapy; pulmonary embolism; venous thromboembolism.

MeSH terms

Adult
Aged
Anticoagulants* / adverse effects
Anticoagulants* / therapeutic use
COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Female
Humans
Male
Middle Aged
Recurrence
Venous Thromboembolism* / prevention & control
Withholding Treatment

Substances

Anticoagulants
COVID-19 Vaccines

Abstract

MeSH terms

Substances

Grants and funding